Tobias Bexte

436 total citations
14 papers, 271 citations indexed

About

Tobias Bexte is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Tobias Bexte has authored 14 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Tobias Bexte's work include CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (11 papers) and RNA Interference and Gene Delivery (3 papers). Tobias Bexte is often cited by papers focused on CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (11 papers) and RNA Interference and Gene Delivery (3 papers). Tobias Bexte collaborates with scholars based in Germany, United Kingdom and France. Tobias Bexte's co-authors include Evelyn Ullrich, Jessica Hartmann, Winfried S. Wels, Nawid Albinger, Toni Cathomen, Ute Modlich, Ulrike Koehl, Axel Schambach, Jamal Alzubi and Emilia Salzmann‐Manrique and has published in prestigious journals such as Blood, Frontiers in Immunology and Journal of Leukocyte Biology.

In The Last Decade

Tobias Bexte

11 papers receiving 266 citations

Peers

Tobias Bexte

ONCOL

IMMUN

GENET

HEMAT

Nicholas Veomett United States

Hans De Reu Belgium

Lorenz Jahn Netherlands

Brian Groff United States

Veronica Zanon Italy

Erik Alcantar-Orozco Belgium

Galit Eisenberg Israel

Brianna Flynn United States

Cheryl A. Cox United States

Andrew W. Daman United States

Nicholas Veomett United States

Tobias Bexte

246 ×1.1

ONCOL

171 ×0.8

IMMUN

128 ×1.6

44 ×0.8

GENET

23 ×1.2

HEMAT

Citations per year, relative to Tobias Bexte Tobias Bexte (= 1×) peers Nicholas Veomett

Countries citing papers authored by Tobias Bexte

Since Specialization

Citations

This map shows the geographic impact of Tobias Bexte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias Bexte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias Bexte more than expected).

Fields of papers citing papers by Tobias Bexte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias Bexte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias Bexte. The network helps show where Tobias Bexte may publish in the future.

Co-authorship network of co-authors of Tobias Bexte

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias Bexte. A scholar is included among the top collaborators of Tobias Bexte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias Bexte. Tobias Bexte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Bexte, Tobias, et al.. (2025). Migration Dynamics of Human NK Cell Preparations in Microchannels and Their Invasion Into Patient‐Derived Tissue. Journal of Cellular and Molecular Medicine. 29(7). e70481–e70481.

Bexte, Tobias, Stephanie Hehlgans, Florian Rothweiler, et al.. (2025). Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy. Journal for ImmunoTherapy of Cancer. 13(7). e011330–e011330.

Fazeli, Alireza, Evelyn Ullrich, Toni Cathomen, & Tobias Bexte. (2025). Engineering with care: safety assessment platforms for CRISPR-modified natural killer cells. Frontiers in Immunology. 16. 1711414–1711414.

Bexte, Tobias & Dimitrios L. Wagner. (2025). Next-generation multiplex-edited CAR-NK cells: more edits, more power?. Journal for ImmunoTherapy of Cancer. 13(9). e012841–e012841. 1 indexed citations

Bexte, Tobias, Lacramioara Botezatu, Csaba Miskey, et al.. (2024). Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors. Molecular Therapy. 32(7). 2357–2372. 24 indexed citations

Bexte, Tobias, Evelyn Ullrich, Andreas Loth, et al.. (2023). The RHOA Mutation G17V Does Not Lead to Increased Migration of Human Malignant T Cells but Is Associated with Matrix Remodelling. Cancers. 15(12). 3226–3226. 1 indexed citations

Albinger, Nawid, Tobias Bexte, Jamal Alzubi, et al.. (2023). P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.. HemaSphere. 7(S3). e71265f8–e71265f8. 1 indexed citations

Bexte, Tobias, et al.. (2023). Nonviral technologies can pave the way for CAR-NK cell therapy. Journal of Leukocyte Biology. 114(5). 475–486. 15 indexed citations

Bexte, Tobias, Jamal Alzubi, Ralf Schubert, et al.. (2022). CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. OncoImmunology. 11(1). 2081415–2081415. 52 indexed citations

10.

Albinger, Nawid, Tobias Bexte, Jamal Alzubi, et al.. (2022). CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML. Blood. 140(Supplement 1). 4558–4559. 16 indexed citations

11.

Bexte, Tobias, Lacramioara Botezatu, Csaba Miskey, et al.. (2021). Non-Viral Sleeping Beauty Transposon Engineered CD19-CAR-NK Cells Show a Safe Genomic Integration Profile and High Antileukemic Efficiency. Blood. 138(Supplement 1). 2797–2797. 11 indexed citations

12.

Bexte, Tobias, Nawid Albinger, Andréas Mackensen, et al.. (2021). Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy. Cancers. 13(6). 1481–1481. 28 indexed citations

13.

Bexte, Tobias, Jessica Hartmann, Ulrike Koehl, et al.. (2020). High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Frontiers in Immunology. 10. 3123–3123. 90 indexed citations

14.

Albinger, Nawid, et al.. (2020). Immunotherapy with NK cells: recent developments in gene modification open up new avenues. OncoImmunology. 9(1). 1777651–1777651. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact